Intracerebrally Applied Botulinum Neurotoxin in Experimental Neuroscience

Title:Intracerebrally Applied Botulinum Neurotoxin in Experimental Neuroscience

Volume: 14 Issue: 1

Author(s): Alexander Hawlitschka, Veronica Antipova, Oliver Schmitt, Martin Witt, Reiner Benecke, Eilhard Mix and Andreas Wree

Affiliation:

Keywords: Botulinum neurotoxin, dementia, epilepsy, hippocampus, ischemia, Parkinson’s disease, spinal cord, striatum

Abstract: The use of botulinum neurotoxins (BoNTs) for therapeutic purposes in neuromuscular disorders and peripheral hypercholinergic conditions as well as in aesthetic medicine is widespread and common. BoNTs are also able to block the release of a wide range of transmitters from presynaptic boutons. Therefore, application of BoNTs directly in the central nervous system (CNS) is currently under study with respect to basic research and potentially as a new therapeutic strategy of neurological diseases. Investigations concentrate on effects of intracerebral and intraspinal application of BoNTs in rodents on the impact on spinal, nuclear, limbic and cortical neuronal circuits. In animal model first promising BoNTinduced therapeutical benefit has been shown in the treatment of pain, epilepsy, stroke and Parkinson’s disease.

Cite this article as:

Hawlitschka Alexander, Antipova Veronica, Schmitt Oliver, Witt Martin, Benecke Reiner, Mix Eilhard and Wree Andreas, Intracerebrally Applied Botulinum Neurotoxin in Experimental Neuroscience, Current Pharmaceutical Biotechnology 2013; 14 (1) . https://dx.doi.org/10.2174/1389201011314010015